Combination of sofosbuvir and velpatasvir (Epclusa®)
Authors:
P. Urbánek
Authors‘ workplace:
Interní klinika 1. LF UK a ÚVN Praha
Published in:
Gastroent Hepatol 2016; 70(6): 553-554
Category:
Drug Profile
Sources
1. SPC Epclusa®, Datum první registrace: 6. července 2016, datum poslední revize textu: červenec 2016.
2. Younossi ZM, Stepanova M, Feld J et al. Sofosbuvir/ velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol 2016; 65(1): 33– 39. doi: 10.1016/j.jhep.2016.02.042.
3. Younossi ZM, Stepanova M, Sulkowski Met al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from ASTRAL-2 and -3 clinical trials. Clin Infect Dis 2016; 63(8): 1042– 1048. doi: 10.1093/cid/ciw496.
4. Foster GR, Afdhal N, Roberts SK et al. Sofosbuvir and velpatasvir for HCV genotype 2and 3 infection. N Engl J Med 2015; 373(27): 2608– 2617. doi: 10.1056/ NEJMoa1512612.
5. Curry MP, O’Leary JG, Bzowej N et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N EnglJ Med 2015; 373(27): 2618– 2628. doi: 10.1056/NEJMoa1512614.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2016 Issue 6
Most read in this issue
- Importance of faecal calprotectin in screening and clinical assessment of adult and pediatric patients with inflammatory bowel diseases
- Budesonide MMX (Cortiment® 9 mg) in the treatment of ulcerative colitis in real clinical practice
- Czech Society of Gastroenterology guidelines for diagnostic and therapeutic colonoscopy
- The duodenal-jejunal bypass liner (EndoBarrier®) for the treatment of type 2 diabetes mellitus in obese patients – efficacy and factors predicting optimal effects